Singapore markets open in 8 hours 40 minutes
  • Straits Times Index

    3,201.86
    -3.28 (-0.10%)
     
  • S&P 500

    4,565.09
    +20.19 (+0.44%)
     
  • Dow

    35,758.42
    +81.40 (+0.23%)
     
  • Nasdaq

    15,190.48
    +100.28 (+0.66%)
     
  • BTC-USD

    63,619.47
    +3,668.64 (+6.12%)
     
  • CMC Crypto 200

    1,520.35
    +1,277.67 (+526.48%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Gold

    1,809.90
    +13.60 (+0.76%)
     
  • Crude Oil

    84.04
    +0.28 (+0.33%)
     
  • 10-Yr Bond

    1.6320
    -0.0230 (-1.39%)
     
  • Nikkei

    28,600.41
    -204.44 (-0.71%)
     
  • Hang Seng

    26,132.03
    +5.10 (+0.02%)
     
  • FTSE Bursa Malaysia

    1,587.94
    -0.14 (-0.01%)
     
  • Jakarta Composite Index

    6,625.70
    -18.04 (-0.27%)
     
  • PSE Index

    7,211.54
    -78.07 (-1.07%)
     

PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, September 23, 2021--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX) on behalf of Protagonist stockholders. Our investigation concerns whether Protagonist has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology platform. Protagonist’s pipeline includes rusfertide (PTG-300).

On September 17, 2021, Protagonist issued a press release "announc[ing] the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold." The press release further stated that "[t]he clinical hold follows Protagonist’s notification to the FDA of a recent non-clinical finding in a 26-week rasH2 transgenic mouse model study. The rasH2 model is designed to detect signals related to tumorigenicity, and benign and malignant subcutaneous skin tumors were observed in this study."

Following this news, Protagonist’s stock price fell $28.60 per share, or 62%, to close at $17.53 per share on September 17, 2021.

If you purchased or otherwise acquired Protagonist shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210922006041/en/

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting